Jun-Ping Wei
- Hematology top 5%
- Acute Myeloid Leukemia Research 6
- Immunology top 10%
- Immunotherapy and Immune Responses 9
- Oncology top 10%
- HER2/EGFR in Cancer Research 6
- CAR-T cell therapy research 5
- Cancer Immunotherapy and Biomarkers 4
- Cancer Research top 10%
-
- Glycosylation and Glycoproteins Research 4
-
- Monoclonal and Polyclonal Antibodies Research 10
-
- Bone and Dental Protein Studies 4
- Co-authors
- H. Kim LyerlyMark WunderlichJames C. MulloyZachary C. HartmanGangjun LeiHongtao GuoMichael A. MorseYi Zheng
- Cited by
- HematologyImmunologyOncology
- Journals
- Blood (4 papers)JCI Insight (3 papers)Biochemical and Biophysical Research Communications (3 papers)
- Partner nations
- United StatesChinaCanada
In The Last Decade
Jun-Ping Wei
41 papers receiving 1.2k citations
Hit Papers
Peers
Comparison fields: 5 of 88
- Hematology 237
- Immunology 366
- Oncology 425
- Cancer Research 169
- Molecular Biology 657
Countries citing papers authored by Jun-Ping Wei
This map shows the geographic impact of Jun-Ping Wei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jun-Ping Wei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jun-Ping Wei more than expected).
Fields of papers citing papers by Jun-Ping Wei
This network shows the impact of papers produced by Jun-Ping Wei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jun-Ping Wei. The network helps show where Jun-Ping Wei may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Jun-Ping Wei, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)breakdown → | 2025 | 29 |
| 2 | 2024 | 2 | |
| 3 | 2024 | 3 | |
| 4 | 2024 | 1 | |
| 5 | 2024 | 5 | |
| 6 | 2024 | 1 | |
| 7 | 2023 | 7 | |
| 8 | 2023 | 6 | |
| 9 | 2023 | 7 | |
| 10 | 2020 | 23 | |
| 11 | 2019 | 83 | |
| 12 | 2018 | 15 | |
| 13 | 2012 | 78 | |
| 14 | 2011 | 157 | |
| 15 | 2010 | 21 | |
| 16 | 2009 | 19 | |
| 17 | 2008 | 54 | |
| 18 | 2007 | 1 | |
| 19 | 2004 | 38 | |
| 20 | 2001 | 7 |
About Jun-Ping Wei
Jun-Ping Wei is a scholar working on Immunology, Oncology, Hematology, Radiology, Nuclear Medicine and Imaging and Cancer Research, having authored 41 papers that have together received 1.2k indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (10 papers), Immunotherapy and Immune Responses (9 papers), HER2/EGFR in Cancer Research (6 papers), Acute Myeloid Leukemia Research (6 papers), CAR-T cell therapy research (5 papers), Glycosylation and Glycoproteins Research (4 papers), Bone and Dental Protein Studies (4 papers) and Cancer Immunotherapy and Biomarkers (4 papers). The work is most often cited by research in Hematology (237 citations), Immunology (366 citations), Oncology (425 citations), Cancer Research (169 citations) and Molecular Biology (657 citations). Jun-Ping Wei has collaborated with scholars based in United States, China and Canada. Frequent co-authors include H. Kim Lyerly, Mark Wunderlich, James C. Mulloy, Zachary C. Hartman, Gangjun Lei, Hongtao Guo, Michael A. Morse, Yi Zheng, Takuya Osada and Amy Hobeika. Their work appears in journals such as Blood, JCI Insight, Biochemical and Biophysical Research Communications, Breast Cancer Research and Journal of Biological Chemistry.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.